Compare NIKI & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NIKI | ARTL |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5M | 1.4M |
| IPO Year | 2018 | 2014 |
| Metric | NIKI | ARTL |
|---|---|---|
| Price | $1.87 | $2.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.7K | ★ 32.3K |
| Earning Date | 11-10-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.88 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.78 | $0.52 |
| 52 Week High | $10.39 | $179.19 |
| Indicator | NIKI | ARTL |
|---|---|---|
| Relative Strength Index (RSI) | 22.57 | 32.73 |
| Support Level | N/A | $0.52 |
| Resistance Level | $5.17 | $6.81 |
| Average True Range (ATR) | 0.35 | 0.17 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 8.54 | 18.33 |
Niki BioSolutions Inc is a clinical-stage life sciences company focused on unmet medical needs and providing genomic and biomarker testing solutions to healthcare providers, research institutions, and life sciences organizations. Its activities include the development and application of proprietary technologies to support precision medicine across therapeutic areas including brain health and oncology. The company also collaborates with academic centers, disease foundations, and biopharmaceutical companies.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.